PEEL Therapeutics

Half of all men and a third of all women will develop cancer in their lifetime. Cancer treatment today is still not efficient enough and often comes along with devastating side effects.

Product Narrative

PEEL Therapeutics is leading the development of a nanotechnology-based novel therapeutic aimed at treating over half of all human cancers through the restoration of the Guardian of the Genome; an approach based on 55 million years of evolution of cancer prevention in elephants.

PEEL Therapeutics is a Utah-Israel collaborative biotech startup that raised its seed funding of $6.5 M at the end of 2017. PEEL is advancing quickly towards an IND application to the FDA (critical step before first-in-man clinical trials) and expecting to begin a Series A investment round in 12-18 months.